Versant Capital Management Inc lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 840 shares of the biopharmaceutical company’s stock after selling 264 shares during the period. Versant Capital Management Inc’s holdings in Gilead Sciences were worth $56,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV increased its holdings in Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the period. Weaver Consulting Group purchased a new position in Gilead Sciences during the 1st quarter valued at about $34,000. Trustcore Financial Services LLC purchased a new position in Gilead Sciences during the 1st quarter valued at about $34,000. Legacy Advisors LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at about $37,000. Finally, Founders Capital Management increased its holdings in Gilead Sciences by 50.0% during the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 78.85% of the company’s stock.
Shares of GILD stock traded down $0.95 during midday trading on Friday, reaching $64.52. 149,888 shares of the stock were exchanged, compared to its average volume of 5,236,842. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The company has a 50 day simple moving average of $67.26. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. The firm has a market cap of $85.53 billion, a price-to-earnings ratio of 10.50, a PEG ratio of 4.06 and a beta of 1.12.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio is currently 40.98%.
In other news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares in the company, valued at $2,238,277.86. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
A number of research analysts recently issued reports on GILD shares. Wells Fargo & Co upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $68.00 to $88.00 in a report on Monday, July 15th. Morgan Stanley set a $82.00 price target on Gilead Sciences and gave the company a “hold” rating in a report on Monday, July 15th. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Mizuho set a $88.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Oppenheimer set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Friday, July 12th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $82.29.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is a front-end load?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.